Výsledky vyhledávání - "E. Rozochkina"

AB0771 Evaluation of the efficacy of inhibitors of tumor necrosis factor alpha for patients with ankylosing spondylitis in real clinical practice

Autor: E. Rozochkina, E. Koltsova, D. Murtazalieva, E. Zhilyaev, E. Koshkarova, G. Lukina

Publikováno v: Annals of the Rheumatic Diseases. 81:1511.3-1512

BackgroundThe question of the comparative efficacy of tumor necrosis factor-alpha (TNF-α) inhibitors is topical today, because the research data that were distributed in random sequence mainly reflect the efficacy of the only specific drug, and the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ea070a5a5a8684d074c668a85d64fac
https://doi.org/10.1136/annrheumdis-2022-eular.3155

Zobrazit plný text záznamu

POS1310 LONG - TERM OUTCOMES IN ADULT PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

Autor: E. Kiseleva, E. Koltsova, E. Volnukhin, N. Savenkova, A. Klimets, E. Rozochkina, A. Kovshik, G. Lukina

Publikováno v: Annals of the Rheumatic Diseases. 81:993.1-993

BackgroundSystemic juvenile idiopathic arthritis (sJIA) debuts in childhood and persists throughout the patient’s lifetime. Currently there is not enough information about the course and therapeutic approaches in patients who have reached the age o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d5bd05afa64cd86ec256556a9dee4357
https://doi.org/10.1136/annrheumdis-2022-eular.2754

Zobrazit plný text záznamu

AB0703 THE COURSE OF COVID-19 INFECTION IN PATIENTS WITH ARTHRITIS RECEIVING TARGETED DMARDS

Autor: K. Lytkina, Galina Lukina, E. Rozochkina, E. Shmidt, E. Zhilyaev, E. Koltsova

Publikováno v: Annals of the Rheumatic Diseases. 80:1383.3-1384

Background:WHO declared the COVID-19 outbreak as a pandemic on March 12th, 2020. Assessing the risk of severe course in patients with rheumatic diseases, especially those who receive targeted immunosuppressive treatment, is an urgent problem for rheu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::db5e8c7d4654b5ff31c454dce6c65700
https://doi.org/10.1136/annrheumdis-2021-eular.3867

Zobrazit plný text záznamu

AB0475 COMPARATIVE EFFECTIVENESS OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN REAL CLINICAL PRACTICE ACCORDING TO THE MOSCOW UNIFIED ARTHRITIS REGISTER (MUAR)

Autor: Galina Lukina, A. Zagrebneva, E. Koltsova, E. Zhilyaev, K. Lytkina, E. Rozochkina, E. Shmidt

Publikováno v: Annals of the Rheumatic Diseases. 80:1265.1-1265

Background:This study is the first analysis of biological disease-modifying antirheumatic drugs (bDMARDs) for ankylosing spondylitis (AS) within the Moscow Unified Arthritis Register (MUAR).Objectives:to compare the effectiveness of bDMARDs in patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a6216ec5aab3333991cccee6fc2d18a3
https://doi.org/10.1136/annrheumdis-2021-eular.2819

Zobrazit plný text záznamu

POS0937 TREATMENT SURVIVAL ON BIOLOGICS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS – DATA FROM MOSCOW UNIFIED ARTHRITIS REGISTRY (MUAR)

Autor: E. Koltsova, E. Rozochkina, Galina Lukina, E. Shmidt, E. Zhilyaev, K. Lytkina, A. Zagrebneva

Publikováno v: Annals of the Rheumatic Diseases. 80:731.3-732

Background:The number of new biologics in treatment of axial spondyloarthritis (axSpA) is rapidly increasing. It is important to assess timely their place in the treatment of axSpA, especially with regard to retention on therapy.Objectives:To compare

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::688b4b2304c432bc69f0d6b5bf0b41c4
https://doi.org/10.1136/annrheumdis-2021-eular.3642

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání